CC BY 4.0 · Rev Bras Ginecol Obstet 2022; 44(06): 593-601
DOI: 10.1055/s-0042-1742314
Review Article

Main Complications during Pregnancy and Recommendations for Adequate Antenatal Care in Sickle Cell Disease: A Literature Review

Principais complicações durante a gestação e recomendações para o cuidado antenatal na doença falciforme: Revisão da literatura
1   Department of Obstetrics and Gynecology, Universidade Estadual de Campinas, Campinas, SP, Brazil
,
1   Department of Obstetrics and Gynecology, Universidade Estadual de Campinas, Campinas, SP, Brazil
,
2   Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington, United States
,
1   Department of Obstetrics and Gynecology, Universidade Estadual de Campinas, Campinas, SP, Brazil
,
1   Department of Obstetrics and Gynecology, Universidade Estadual de Campinas, Campinas, SP, Brazil
› Author Affiliations

Abstract

Sickle cell disease (SCD) is the most common monogenic disease worldwide, with a variable prevalence in each continent. A single nucleotide substitution leads to an amino-acid change in the β-globin chain, altering the normal structure ofhemoglobin, which is then called hemoglobin S inherited in homozygosity (HbSS) or double heterozygosity (HbSC, HbSβ), and leads to chronic hemolysis, vaso-occlusion, inflammation, and endothelium activation. Pregnant women with SCD are at a higher risk of developing maternal and perinatal complications. We performed a narrative review of the literature considering SCD and pregnancy, the main clinical and obstetrical complications, the specific antenatal care, and the follow-up for maternal and fetal surveillance. Pregnant women with SCD are at a higher risk of developing clinical and obstetric complications such as pain episodes, pulmonary complications, infections, thromboembolic events, preeclampsia, and maternal death. Their newborns are also at an increased risk of developing neonatal complications: fetal growth restriction, preterm birth, stillbirth. Severe complications can occur in patients of any genotype. We concluded that SCD is a high-risk condition that increases maternal and perinatal morbidity and mortality. A multidisciplinary approach during pregnancy and the postpartum period is key to adequately diagnose and treat complications.

Resumo

Doença falciforme (DF) é a condição genética mais comum no mundo, com uma prevalência variável nos continentes. A substituição de um nucleotídeo muda um aminoácido na cadeia da β globina, e altera a estrutura normal da hemoglobina, que é então chamada de hemoglobina S, e pode ser herdada em homozigose (HbSS) ou heterozigose (HbSC, HbSβ), e leva a hemólise crônica, vaso-oclusão, inflamação, e ativação endotelial. Realizou-se uma revisão narrativa da literatura considerando doença falciforme e gestação, as complicações clínicas e obstétricas, o cuidado antenatal específico, e o seguimento para monitoramento materno e fetal. Gestantes com DF têm maior risco de desenvolver complicações clínicas e obstétricas, como crises dolorosas, complicações pulmonares, infecções, eventos tromboembólicos, pré-eclâmpsia, e morte materna. E seus recém-nascidos correm maior risco de desenvovler complicações neonatais: restrição de crescimento fetal, prematuridade e óbito fetal/neonatal. Complicações graves podem ocorrer em qualquer genótipo da doença. Concluiu-se que DF é uma condição de alto risco que aumenta a morbimortalidade materna e perinatal. Um seguimento com abordagem multidisciplinar na gestação e puerpério é fundamental para o diagnóstico e o tratamento das complicações.



Publication History

Received: 03 August 2021

Accepted: 03 November 2021

Article published online:
09 February 2022

© 2022. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 
  • References

  • 1 Serjeant GR. The emerging understanding of sickle cell disease. Br J Haematol 2001; 112 (01) 3-18
  • 2 Howard J, Oteng-Ntim E. The obstetric management of sickle cell disease. Best Pract Res Clin Obstet Gynaecol 2012; 26 (01) 25-36
  • 3 Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M. et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013; 381 (9861): 142-151
  • 4 Angastiniotis M, Modell B, Englezos P, Boulyjenkov V. Prevention and control of haemoglobinopathies. Bull World Health Organ 1995; 73 (03) 375-386
  • 5 Asnani MR, Quimby KR, Bennett NR, Francis DK. Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications. Cochrane Database Syst Rev 2016; 10 (10) CD011175
  • 6 Santo AH. Sickle cell disease related mortality in Brazil, 2000-2018. Hematol Transfus Cell Ther 2020; •••: S2531-1379 (20)31299-2. Doi: 10.1016/j.htct.2020.09.154[ahead of print]
  • 7 Silva-Pinto AC, Alencar de Queiroz MC, Antoniazzo Zamaro PJ, Arruda M, Pimentel Dos Santos H. The Neonatal Screening Program in Brazil, Focus on Sickle Cell Disease (SCD). Int J Neonatal Screen 2019; 5 (01) 11
  • 8 Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet 2017; 390 (10091): 311-323
  • 9 Weatherall DJ. ABC of clinical haematology. The hereditary anaemias. BMJ 1997; 314 (7079): 492-496
  • 10 Oteng-Ntim E, Meeks D, Seed PT, Webster L, Howard J, Doyle P. et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood 2015; 125 (21) 3316-3325
  • 11 Oteng-Ntim E, Ayensah B, Knight M, Howard J. Pregnancy outcome in patients with sickle cell disease in the—K–a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease. Br J Haematol 2015; 169 (01) 129-137
  • 12 Smith-Whitley K. Complications in pregnant women with sickle cell disease. Hematology (Am Soc Hematol Educ Program) 2019; 2019 (01) 359-366
  • 13 Smith JA, Espeland M, Bellevue R, Bonds D, Brown AK, Koshy M. Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease. Obstet Gynecol 1996; 87 (02) 199-204
  • 14 Wilson NO, Ceesay FK, Hibbert JM, Driss A, Obed SA, Adjei AA. et al. Pregnancy outcomes among patients with sickle cell disease at Korle-Bu Teaching Hospital, Accra, Ghana: retrospective cohort study. Am J Trop Med Hyg 2012; 86 (06) 936-942
  • 15 Boulet SL, Okoroh EM, Azonobi I, Grant A, Craig Hooper W. Sickle cell disease in pregnancy: maternal complications in a Medicaid-enrolled population. Matern Child Health J 2013; 17 (02) 200-207
  • 16 Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L. et al. Sickle cell disease. Nat Rev Dis Primers 2018; 4: 18010
  • 17 Ozdogu H, Sozer O, Boga C, Kozanoglu L, Maytalman E, Guzey M. Flow cytometric evaluation of circulating endothelial cells: a new protocol for identifying endothelial cells at several stages of differentiation. Am J Hematol 2007; 82 (08) 706-711
  • 18 Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet 2001; 357 (9257): 680-683
  • 19 Telfer P, Coen P, Chakravorty S, Wilkey O, Evans J, Newell H. et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica 2007; 92 (07) 905-912
  • 20 Rogers DT, Molokie R. Sickle cell disease in pregnancy. Obstet Gynecol Clin North Am 2010; 37 (02) 223-237
  • 21 Hassell K. Pregnancy and sickle cell disease. Hematol Oncol Clin North Am. 2005; 19 (05) 903-16 , vii-viii.
  • 22 Silva-Pinto AC, de Oliveira Domingues Ladeira S, Brunetta DM, De Santis GC, de Lucejáulo I, Covas DT. Sickle cell disease and pregnancy: analysis of 34 patients followed at the Regional Blood Center of Ribeirão Preto, Brazil. Rev Bras Hematol Hemoter 2014; 36 (05) 329-333
  • 23 Barfield WD, Barradas DT, Manning SE, Kotelchuck M, Shapiro-Mendoza CK. Sickle cell disease and pregnancy outcomes: women of African descent. Am J Prev Med 2010; 38 (4, Suppl) S542-S549
  • 24 Afolabi BB, Iwuala NC, Iwuala IC, Ogedengbe OK. Morbidity and mortality in sickle cell pregnancies in Lagos, Nigeria: a case control study. J Obstet Gynaecol 2009; 29 (02) 104-106
  • 25 Al-Farsi SH, Al-Riyami NM, Al-Khabori MK, Al-Hunaini MN. Maternal complications and the association with baseline variables in pregnant women with sickle cell disease. Hemoglobin 2013; 37 (03) 219-226
  • 26 Andemariam B, Browning SL. Current management of sickle cell disease in pregnancy. Clin Lab Med 2013; 33 (02) 293-310
  • 27 Nomura RM, Igai AM, Tosta K, da Fonseca GH, Gualandro SF, Zugaib M. [Maternal and perinatal outcomes in pregnancies complicated by sickle cell dijáses]. Rev Bras Ginecol Obstet 2010; 32 (08) 405-411
  • 28 Silva FAC, Ferreira ALCG, Hazin-Costa MF, Dias MLG, Araújo AS, Souza AI. Adverse clinical and obstetric outcomes among pregnant women with different sickle cell disease genotypes. Int J Gynaecol Obstet 2018; 143 (01) 89-93
  • 29 Elenga N, Adeline A, Balcaen J, Vaz T, Calvez M, Terraz A. et al. Pregnancy in sickle cell disease is a very high-risk situation: an observational study. Obstet Gynecol Int 2016; 2016: 9069054
  • 30 Villers MS, Jamison MG, De Castro LM, James AH. Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol 2008; 199 (02) 125.e1-125.e5
  • 31 Dare FO, Makinde OO, Faasuba OB. The obstetric performance of sickle cell disease patients and homozygous hemoglobin C disease patients in Ile-Ife, Nigeria. Int J Gynaecol Obstet 1992; 37 (03) 163-168
  • 32 Say L, Souza JP, Pattinson RC. WHO working group on Maternal Mortality and Morbidity classifications. Matern—near miss–towards a standard tool for monitoring quality of maternal health care. Best Pract Res Clin Obstet Gynaecol 2009; 23 (03) 287-296
  • 33 Penney G, Brace V. Near miss audit in obstetrics. Curr Opin Obstet Gynecol 2007; 19 (02) 145-150
  • 34 Lewis G. Beyond the numbers: reviewing maternal deaths and complications to make pregnancy safer. Br Med Bull 2003; 67: 27-37
  • 35 Resejáe Cardoso PS, Lopes Pessoa de Aguiar RA, Viana MB. Clinical complications in pregnant women with sickle cell disease: prospective study of factors predicting maternal death or near miss. Rev Bras Hematol Hemoter 2014; 36 (04) 256-263
  • 36 Souza JP, Cecatti JG, Parpinelli MA, Serruya SJ, Amaral E. Appropriate criteria for identification of near-miss maternal morbidity in tertiary care facilities: a cross sectional study. BMC Pregnancy Childbirth 2007; 7: 20
  • 37 Boafor TK, Olayemi E, Galadanci N, Hayfron-Benjamin C, Dei-Adomakoh Y, Segbefia C. et al. Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG 2016; 123 (05) 691-698
  • 38 Inparaj S, Buckingham M, Oakley L, Seed PT, Lucas S, Oteng-Ntim E. Pulmonary complications for women with sickle cell disease in pregnancy: systematic review and meta-analysis. Thorax 2020; 75 (07) 568-575
  • 39 Rajab KE, Issa AA, Mohammed AM, Ajami AA. Sickle cell disease and pregnancy in Bahrain. Int J Gynaecol Obstet 2006; 93 (02) 171-175
  • 40 Kant S, Kaur R, Goel AD, Malhotra S, Haldar P, Kumar R. Anemia at the time of delivery and its association with pregnancy outcomes: A study from a secondary care hospital in Haryana, India. Indian J Public Health 2018; 62 (04) 315-318
  • 41 Suryanarayana R, Chandrappa M, Santhuram AN, Prathima S, Sheela SR. Prospective study on prevalence of anemia of pregnant women and its outcome: A community based study. J Family Med Prim Care 2017; 6 (04) 739-743
  • 42 Scholl TO. Maternal iron status: relation to fetal growth, length of gestation, and iron endowment of the neonate. Nutr Rev 2011; 69 (Suppl. 01) S23-S29
  • 43 Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW. Nutrition Impact Model Study Group (anaemia). Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. BMJ 2013; 346: f3443
  • 44 Sukrat B, Wilasrusmee C, Siribumrungwong B, McEvoy M, Okascharoen C, Attia J. et al. Hemoglobin concentration and pregnancy outcomes: a systematic review and meta-analysis. BioMed Res Int 2013; 2013: 769057
  • 45 Sun PM, Wilburn W, Raynor BD, Jamieson D. Sickle cell disease in pregnancy: twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia. Am J Obstet Gynecol 2001; 184 (06) 1127-1130
  • 46 Baptista LC, Costa ML, Ferreira R, Albuquerque DM, Lanaro C, Fertrin KY. et al. Abnormal expression of inflammatory genes in placentas of women with sickle cell anemia and sickle hemoglobin C disease. Ann Hematol 2016; 95 (11) 1859-1867
  • 47 Chou ST, Fasano RM. Management of patients with sickle cell disease using transfusion therapy: guidelines and complications. Hematol Oncol Clin North Am 2016; 30 (03) 591-608
  • 48 ACOG Committee on Obstetrics. ACOG Practice Bulletin No. 78: hemoglobinopathies in pregnancy. Obstet Gynecol 2007; 109 (01) 229-237
  • 49 Malinowski AK, Shehata N, D'Souza R, Kuo KH, Ward R, Shah PS. et al. Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis. Blood 2015; 126 (21) 2424-2435, quiz 2437
  • 50 Asma S, Kozanoglu I, Tarım E, Sarıturk C, Gereklioglu C, Akdeniz A. et al. Prophylactic red blood cell exchange may be beneficial in the management of sickle cell disease in pregnancy. Transfusion 2015; 55 (01) 36-44
  • 51 Grossetti E, Carles G, El Guindi W, Seve B, Montoya Y, Creveuil C. et al. Selective prophylactic transfusion in sickle cell disease. Acta Obstet Gynecol Scand 2009; 88 (10) 1090-1094
  • 52 Gilli SC, De Paula EV, Biscaro FP, Marques JF, Costa FF, Saad ST. Third-trimester erythrocytapheresis in pregnant patients with sickle cell disease. Int J Gynaecol Obstet 2007; 96 (01) 8-11
  • 53 Koshy M, Chisum D, Burd L, Orlina A, How H. Management of sickle cell anemia and pregnancy. J Clin Apher 1991; 6 (04) 230-233
  • 54 Howard RJ, Tuck SM, Pearson TC. Pregnancy in sickle cell disease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. Br J Obstet Gynaecol 1995; 102 (12) 947-951
  • 55 Dias Zanette AM, de Souza Gonçalves M, Vilasboas Schettini L, Magalhães Aguiar L, Santos Bahia RC, Vasconcelos Nogueira LA. et al. Alloimmunization and clinical profile of sickle cell disease patients from Salvador-Brazil. Ethn Dis 2010; 20 (02) 136-141
  • 56 Burton GJ, Fowden AL. The placenta: a multifaceted, transient organ. Philos Trans R Soc Lond B Biol Sci.. 2015; 370 (1663): 20140066
  • 57 Trampont P, Roudier M, Andrea AM, Nomal N, Mignot TM, Leborgne-Samuel Y. et al. The placental-umbilical unit in sickle cell disease pregnancy: a model for studying in vivo functional adjustments to hypoxia in humans. Hum Pathol 2004; 35 (11) 1353-1359
  • 58 Thame M, Lewis J, Trotman H, Hambleton I, Serjeant G. The mechanisms of low birth weight in infants of mothers with homozygous sickle cell disease. Pediatrics 2007; 120 (03) e686-e693
  • 59 Mifsud W, Sebire NJ. Placental pathology in early-onset and late-onset fetal growth restriction. Fetal Diagn Ther 2014; 36 (02) 117-128
  • 60 Lees C, Marlow N, Arabin B, Bilardo CM, Brezinka C, Derks JB. et al; TRUFFLE Group. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol 2013; 42 (04) 400-408
  • 61 Pérez-Cruz M, Cruz-Lemini M, Fernánjáz MT, Parra JA, Bartrons J, Gómez-Roig MD. et al. Fetal cardiac function in late-onset intrauterine growth restriction vs small-for-gestational age, as defined by estimated fetal weight, cerebroplacental ratio and uterine artery Doppler. Ultrasound Obstet Gynecol 2015; 46 (04) 465-471
  • 62 American College of Obstetricians Gynecologists. ACOG Practice bulletin no. 134: fetal growth restriction. Obstet Gynecol 2013; 121 (05) 1122-1133
  • 63 Ballas SK, Darbari DS. Review/overview of pain in sickle cell disease. Complement Ther Med 2020; 49: 102327
  • 64 World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015
  • 65 Pecker LH, Darbari DS. Psychosocial and affective comorbidities in sickle cell disease. Neurosci Lett 2019; 705: 1-6
  • 66 Adam SS, Flahiff CM, Kamble S, Telen MJ, Reed SD, De Castro LM. Depression, quality of life, and medical resource utilization in sickle cell disease. Blood Adv 2017; 1 (23) 1983-1992
  • 67 Hyacinth HI, Gee BE, Hibbert JM. The role of nutrition in sickle cell disease. Nutr Metab Insights 2010; 3: 57-67
  • 68 Baldanzi G, Traina F, Marques Neto JF, Santos AO, Ramos CD, Saad ST. Low bone mass density is associated with hemolysis in Brazilian patients with sickle cell disease. Clinics (São Paulo) 2011; 66 (05) 801-805
  • 69 Ulrich U, Miller PB, Eyre DR, Chesnut III CH, Schlebusch H, Soules MR. Bone remodeling and bone mineral density during pregnancy. Arch Gynecol Obstet 2003; 268 (04) 309-316